Speakers

Dr Johannes Blümel
Paul-Ehrlich-Institut, Federal Agency for Vaccines and Biomedicines

Dr Albrecht Gröner
PathoGuard Consult

Dr Michael Ruffing
Boehringer Ingelheim Pharma

Michael Schiffer
CSL Behring

Virus and TSE Safety made simple
All you need to know

05/06 March 2024 | Barcelona, Spain

Highlights

- Overview about relevant Aspects of Virology
- The Impact on the Manufacture of Biopharmaceuticals/Biologics
- Current Detection, Inactivation and removal Techniques
- Regulatory Background
- Design and Documentation of Validation Studies
- Eliminate Misunderstandings on TSE
- Pathogen Safety Risk Assessment
- Interactive Workshops

With interactive Workshop Sessions
Objectives

It is the aim of this course to enlighten this world between “dead and alive”.

The nature of viruses postulates significant differences to microorganisms. This uniqueness poses particular challenges to the detection, inactivation and removal of viruses.

All these specifics will be discussed in detail at this education course – in an understandable manner.

Another threat poses TSE (Transmissible spongiform encephalopathy). Numerous studies have been conducted to understand the route of transmission and the causing agents better. Nevertheless, misunderstandings and rumours circulate and cumulate in the statement: “We need a TSE-certificate for our activated charcoal.”

This course will give you a scientifically sound introduction into the field of TSE and the impact on the pharmaceutical industry.

Background

The current situation has shown us that the development and production of vaccines can also attract enormous public attention. This makes it all the more important, especially when it comes to approval and production under time pressure, that the quality standards of good manufacturing practice are observed.

Virus safety is one of the major concerns in the development and production of biopharmaceuticals and biologics. Huge efforts are undertaken to prevent viral contamination. A series of guidelines was dedicated to that topic exclusively.

For many people who are involved in the development and production of biopharmaceuticals and biologics the world of viruses is a “black box”.

Target Audience

This Education Course is directed to responsible personnel involved in the development and production of biopharmaceuticals and biologics

- Research & Development
- Quality Assurance
- Regulatory Affairs
- Production
- Engineering
- Quality Control

It is also useful for service providers, such as contract research organisations and contract manufacturers.

Programme

Elemental (Basic) Virology

- Physiology (if you can use such a word)
- Replication cycles
- Vectors
- Resistance properties

Exogenous (Adventitious) and Endogenous Virus

- Terminology
- Viral safety approach
- Effects of virus infection on host cell
- Detection of exogenous / endogenous virus

Design and Documentation of Virus Validation Studies

- Sources
- Virus spike preparation
- Cytotoxicity/interference
- Infectivity assay or NAT assay
- Down scaling of manufacturing step

Methods for Virus Inactivation and Virus Removal

- Virus reduction by manufacturing process steps for protein purification
- Virus reduction by dedicated virus reduction steps
- Robustness of virus reduction methods

Virus Safety of Raw Materials

- Qualification of the material and its supplier
- Sourcing, testing and manufacture of raw materials
- Virus clearance studies
- Testing prior and at production of biotech product

Virus Safety Aspects of Advanced Therapy Medicinal Products (ATMPs)

- Regulatory background/certification
- Gene therapy medicinal products
- Cell-based medicinal products

Pathogen Safety Risk Assessments

- What to consider and how to perform risk assessments regarding pathogen safety, incl. deviations and changes
- Introduction into Segregation Risk Analysis
- Case studies
Virus Safety: Regulatory Background

- ICH Guidelines (ICH Q5A)
- European Guidelines (EMEA)
- European Pharmacopoeia
- Risk assessment
- Clinical trials in Europe

Transmissible Spongiform Encephalopathy (TSE) - Biology

- The nature and transmission of TSE agents (prions)
- Epidemiology
- Methods for detecting TSE agents
- Resistance/inactivation of prions, cleaning/disinfection
- Prion reduction techniques

Transmissible Spongiform Encephalopathy (TSE) - Regulatory

- EU Legislation (food, medicinal products, medicinal devices)
- EMEA TSE note for guidance
- EDQM TSE Certification Procedure
- Regulations for blood and urine derived medicinal products

Interactive Workshops with Case Studies and Examples

During this workshops, the participants develop in small groups approaches to manufacture pathogen safe products, e.g. choosing testing strategies and calculating safety margins.

Moderator

Clemens Mundo, Concept Heidelberg

Social Event

On 05th March you are invited to take part in an evening programme. This is an excellent opportunity to share your experiences with the speakers and colleagues from other companies in a relaxed atmosphere.

Speakers

Dr Johannes Blümel
Paul-Ehrlich-Institut, Federal Agency for Vaccines and Biomedicines, Germany

Johannes started his career in the field of research on virus diagnostics at the University of Bonn. Since 1998 he has been working for the Paul-Ehrlich-Institut, the German Federal Agency for Vaccines and Biomedicines. At present Johannes is heading the section of viral safety. His main areas of responsibility are risk evaluation of medicinal products (blood products, biopharmaceuticals) and applied research. Johannes is also an assessor for the evaluation of the reduction of TSE risk at EDQM.

Dr Albrecht Gröner
PathoGuard Consult, Germany

Albrecht spent many years in R&D of vaccines and plasma derivatives at the Behringwerke and successor companies in Marburg focusing on pathogen safety of biologicals. At present, after retirement from CSL Behring as Head of Pathogen Safety, he consults companies producing plasma and cell culture derived biologicals and devices manufactured with material of human or animal origin in this field.

Dr Michael Ruffing
Boehringer Ingelheim Pharma, Germany

Michael was trained as a post-doc in virology at the German Cancer Research Centre Heidelberg and at Hoffmann-La Roche prior to joining regulatory authorities in Switzerland and Germany. He then joined the GFB Biopharmaceuticals of Boehringer Ingelheim in Biberach. After acting as head of the group virology & contamination detection, Michael is now in the Analytical Development Biologicals Department of the Innovation Unit responsible for adventitious agents topics of Biologicals including virus therapeutics.

Michael Schiffer
Senior Manager Global R&D, CSL Behring, Switzerland

Michael Schiffer worked at Novartis from 2013 to 2020 in various functions in the area of fill & finish of commercial and clinical biopharmaceuticals and their launch. After his start in microbiological quality assurance and then working as a process expert in manufacturing, he headed a quality control laboratory for chemical-physical release and stability testing. Since 2020 within Research and Development at CSL Behring in the Global Pathogen Safety department, he provides global support to general matters related to Pathogen Safety and leads the scientific support team for Switzerland.
General terms and conditions
If you cannot attend the conference you have two options:
1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees:
   - Cancellation until 4 weeks prior to the conference 10 %,
   - Cancellation until 3 weeks prior to the conference 25 %,
   - Cancellation until 2 weeks prior to the conference 50 %,
   - Cancellation within 2 weeks prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message.

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

CONCEPT HEIDELBERG
P.O. Box 101764
Fax +49 (0) 62 21/84 44 34
D-69007 Heidelberg
GERMANY

Reservation Form (Please complete in full)

Title, first name, surname

Department

Company

Important: Please indicate your company’s VAT ID Number

City

ZIP Code

Country

Purchase Order Number, if applicable

Phone / Fax

E-Mail (Please fill in)

WA/26052023